New research from the laboratory of Dr. Elizabeth Leadbetter at the Trudeau Institute may lead to a whole new class of vaccines. Dr. Leadbetter's lab has discovered new properties of a potential vaccine adjuvant that suggest ...
Dec 12, 2011
0
0
Results of the largest genomics study of multiple sclerosis patients ever undertaken have identified more than two dozen new genetic variants linked to disease risk, including some previously implicated in other autoimmune ...
Aug 10, 2011
0
0
Interleukin-10 (IL-10) is an anti-inflammatory cytokine protein that reduces immune responses and staves off autoimmune disease. Now, a research team led by Masato Kubo at the RIKEN Research Center for Allergy and Immunology, ...
Jun 17, 2011
0
0
By digging a little deeper, researchers may have found a potential target for reversing the deadly blood infection sepsis.
Jun 10, 2011
0
0
An experimental cure for Type 1 diabetes has a nearly 80 percent success rate in curing diabetic mice. The results, to be presented Saturday at The Endocrine Society's 93rd Annual Meeting in Boston, offer possible hope of ...
Jun 6, 2011
0
0
A potential new treatment for type 2 diabetes has multiple, positive effects on health and metabolism in mice, reports a study in Nature. The new drug might have potential for treating a variety of disorders in addition to ...
Sep 26, 2019
0
4
A team of Russian scientists has identified the role of the interleukin-6 molecule in the development of allergic asthma. It may comprise a new target for the treatment of this disease. The results are published in Frontiers ...
Dec 18, 2018
0
1
Emerging data on the role of inflammation and the immune system in the development, growth, and spread of breast tumors have focused increased attention on the role cytokines such as interleukin and transforming growth factor-β ...
Jan 13, 2015
0
5
Studying the expression of genes that are dependent on vitamin D makes it possible to identify individuals who will benefit from vitamin D supplementation, shows a University of Eastern Finland study published recently in ...
Aug 13, 2013
0
0
Study findings first presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism, demonstrate the efficacy of canakinumab at tapering corticosteroid (CS) use in patients with SJIA.
Jun 13, 2013
0
0
